Showing 6911-6920 of 7932 results for "".
- Burt's Bees Nature-Based Sensitive Skin Regimen Trumps Dermatologist-recommended Regimenhttps://practicaldermatology.com/news/burts-bees-nature-based-sensitive-skin-regimen-trumps-dermatologist-recommended-regimen/2457860/Burt's Bees nature-based sensitive line outperformed a dermatologist-recommended synthetic control regimen in a study of 120 people with clinically diagnosed sensitive skin from rosacea, atopic dermatitis/eczema, or cosmetic intolerance. The nat
- DermTech Receives State of New York Laboratory Permithttps://practicaldermatology.com/news/dermtech-receives-state-of-new-york-laboratory-permit/2457864/DermTech, Inc., which specializes in non-invasive molecular dermatology, has received permitting from the State of New York, Department of Public Health. The addition of a New York permit to DermTech’s current accreditations, allows it to now provide laboratory services across the
- BrandMD Launches New Tinted, Physical Sunscreenhttps://practicaldermatology.com/news/brandmd-launches-new-tinted-physical-sunscreen/2457863/BrandMD introduced their newest sunscreen, HA Physical Tint SPF 44. HA Physical Tint SPF 44 is a water-resistant, mineral-based formulation to provide well-rounded coverage against UVA and UVB UV radiation. In addition to its chemical-free active ingredients, the formulation also contains antioxi
- Vit D Levels Elevated in Acnehttps://practicaldermatology.com/news/vit-d-levels-higher-in-acne/2457867/Levels of vitamin D are higher in acne patients, compared to age/sex matched controls. Researchers found a significant inverse relation between level of 25 hydroxy vitamin D and severity of acne vulgaris before treatment, according to a study in Journal of Cosmetic Dermatology.
- Dermira Presents Positive Data on Treating Pediatric Patients with Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermira-presents-positive-data-on-treating-pediatric-patients-with-axillary-hyperhidrosis/2457873/Dermira, Inc. presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program showing that when applied topically, the investigational therapy improved disease severity, reduced sweat production and was associated with improved quality of life outcomes for pediat
- Exciplex Phototherapy Device Debuts at AAD 2018https://practicaldermatology.com/news/exciplex-phototherapy-device-debuts-at-aad-2018/2457877/Excimer Therapies Inc., now has the exclusive U.S. distribution rights for the Clarteis SAS exciplex® phototherapy treatment device. Excimer Therapies officially enters the market and will demonstrate the exciplex during t
- Restoration Robotics to Showcase ARTAS Robotic Hair Restoration System at Annual AAD Meetinghttps://practicaldermatology.com/news/restoration-robotics-to-showcase-artas-robotic-hair-restoration-system-at-annual-aad-meeting/2457882/Restoration Robotics, Inc. will showcase the ARTAS Robotic Hair Restoration System at The Annual Meeting of the American Academy of Dermatology (AAD) February 15-18 at the San Diego Convention Center in San Diego, CA. At the meeting, Restoration Robotics will host in-booth presentations a
- Biofrontera Rings Nasdaq Market Closing Bellhttps://practicaldermatology.com/news/biofrontera-rings-nasdaq-closing-bell/2457881/Biofrontera AG the specialist for the treatment of sun-induced skin cancer, visited the Nasdaq MarketSite in Times Square. In honor of the occasion, Prof. Hermann Lübbert, PhD, Chief Executive Officer of Biofrontera rang the Closing Bell
- Aqua Pharmaceuticals Supports Camp Discoveryhttps://practicaldermatology.com/news/aqua-pharmaceuticals-supports-camp-discovery/2457884/Aqua Pharmaceuticals, LLC is demonstrating its commitment to the dermatology community by supporting American Academy of Dermatology’s Camp Discovery and is making a donation up to $5,000 to support the camp
- Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meetinghttps://practicaldermatology.com/news/lilly-new-taltz-data-and-pipeline-update-to-be-presented-at-aad-annual-meeting/2457885/Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include eight abstracts for Tal